HIV/AIDS Clinical Trials in San Antonio

Showing 221-240 of 434 trials

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

NCT02480881

This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the pharmacokinetics (PK) of either ethinyl estradiol (EE) or norethindrone (NE).

Infection, Human Immunodeficiency Virus

ViiV Healthcare26 participantsStarted Jul 2015

Miami, Florida, United States • San Antonio, Texas, United States

COMPLETEDPhase 1< 1 mile

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

NCT02164045

The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in the fasted state, if so desired.

Infection, Human Immunodeficiency Virus

ViiV Healthcare38 participantsStarted Jun 2014

San Antonio, Texas, United States

COMPLETEDPhase 474 miles

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

NCT00082394

The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared.

Infection, Human Immunodeficiency Virus IHIV Infection

GlaxoSmithKlineStarted Apr 2004

Bakersfield, California, United States • Los Angeles, California, United States • Oakland, California, United States +42 more locations

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

HIV/AIDS Trials in Other Cities

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

PRO 140 for Human Immunodeficiency Virus Infection

Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

GW873140 In Combination With Combivir In HIV Infected Subjects

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

Engaging Care for HIV-infected Adolescent Females.

A Novel Method to Determine HIV Incidence Among Youth

CDC-ATN Linkage Evaluation

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

Other Conditions in San Antonio